Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 351

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 351
---
 – |     |         – |     | –      |   |     | 6,054,230 |     | –          |   |     |        6,054,230 |
| December 2023 grant              |     |           – |     |        |   |     | 6,000,126 |     | 6,000,126 |     | –      |   |     |         – |     | (4,282,895 | ) |     |        1,717,231 |
| May 2023 grant                   |     |           – |     |        |   |     |   276,689 |     |   276,689 |     | –      |   |     |         – |     | –          |   |     |          276,689 |
| May 2020 grant                   |     |         838 |     | –      |   |     |         – |     |       838 |     | –      |   |     |         – |     | –          |   |     |              838 |
| October 19 grant                 |     |         392 |     | –      |   |     |         – |     |       392 |     | –      |   |     |         – |     | –          |   |     |              392 |
| Ordinary Shares                  |     |             |     |        |   |     |           |     |           |     |        |   |     |           |     |            |   |     |                  |
| DARA Options                     |     |         138 |     | (10    | ) |     |         – |     |       128 |     | (29    | ) |     |         – |     | –          |   |     |               99 |

| F-13 |

Fair value hierarchy

The Group uses
the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique:

Level 1: quoted
(unadjusted) prices in active markets for identical assets and liabilities;

Level 2: other
techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly;
and

Level 3: techniques
which use inputs that have a significant effect on the recorded fair value that are not based on observable market data.

The fair value
of the Group’s derivative financial liability is measured at fair value on a